J. Safra Asset Management’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.8K Sell
617
-246
-29% -$6.64K ﹤0.01% 338
2026
Q1
$15.6K Buy
863
+660
+325% +$12.6K ﹤0.01% 331
2025
Q4
$4.41K Hold
203
– – ﹤0.01% 447
2025
Q3
$6.62K Buy
203
+2
+1% +$74 ﹤0.01% 288
2025
Q2
$7.13K Buy
201
+9
+5% +$292 ﹤0.01% 322
2025
Q1
$6.51K Buy
192
+164
+586% +$5.88K ﹤0.01% 305
2024
Q4
$918 Hold
28
– – ﹤0.01% 313
2024
Q3
$1.38K Buy
+28
New +$1.49K ﹤0.01% 269

Other funds holding LEGN

J. Safra Asset Management's LEGN Position: Q2 2026 in Review

J. Safra Asset Management reduced its Legend Biotech (LEGN) stake by 29% in Q2 2026, selling an estimated $6.64K and leaving 617 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #338.

J. Safra Asset Management first reported a position in LEGN in Q3 2024 and has held it in 8 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • J. Safra Asset Management held 617 shares of Legend Biotech worth $17.8K as of Q2 2026.
  • J. Safra Asset Management sold 246 Legend Biotech shares in Q2 2026, an estimated $6.64K.
  • Legend Biotech made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #338 holding.
  • J. Safra Asset Management first reported a position in Legend Biotech in Q3 2024 and has held it in 8 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.